Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Restnerve D3 is a fixed-dose combination product developed by Matteo Health Care, specifically formulated for the management of peripheral neuropathy and associated nutritional deficiencies. The medication combines several key neuroprotective agents: methylcobalamin, a neurologically active form of Vitamin B12 that facilitates axonal regeneration and myelin sheath synthesis; thioctic acid (alpha lipoic acid), a potent antioxidant that neutralizes free radicals and improves endoneurial blood flow; and cholecalciferol (Vitamin D3), which supports neuronal health and calcium homeostasis. The formulation is further supplemented with pyridoxine (Vitamin B6) and folic acid, which act as essential cofactors in homocysteine metabolism and other metabolic pathways critical for nerve function. Restnerve D3 is primarily indicated for patients suffering from diabetic neuropathy, idiopathic neuropathy, or nerve damage resulting from chronic nutritional deficiencies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylcobalamin + thioctic acid + cholecalciferol + pyridoxine + folic acid.